21 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
manufacturing processes and facilities, or Apexigen’s marketing programs. Such regulatory investigation could potentially lead to a recall … authorities may withdraw approvals of such product and cause Apexigen to recall Apexigen’s products;
regulatory authorities may require additional
S-4/A
d1zbeu du
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
oq6pvn u1foy0ktxex1
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
425
w203zjf0curov
25 May 23
Business combination disclosure
8:14am
10-K
6psnq3hhrtqsb4u ml
29 Mar 22
Annual report
7:36am
10-Q
0q16iy
15 Nov 21
Quarterly report
7:54am
424B4
8lmojf1i7u esdu
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1
ss8 8hrax4qsiptkr
17 Sep 21
IPO registration
5:00pm
DRS/A
yk4jw2xdxge52wglt8x
10 Sep 21
Draft registration statement (amended)
12:00am
DRS/A
u5khxd6w4w5r 93
4 Aug 21
Draft registration statement (amended)
12:00am